Aldevron News
Aldevron and InDevR partner to test chip-based technology for capping efficiency
February 26, 2025 / by Aldevron
In the years following the 2020 COVID-19 pandemic, mRNA technology has proven to be a game-changer in the field of vaccines and therapeutics. The rapid development and approval of COVID vaccines highlighted the need for efficient and reliable analytical methods. However, traditional methods often rely on expensive and complex instrumentation, which can slow down the optimization of mRNA vaccine constructs. In response to this challenge, InDevR has increased the available assays for their VaxArray platform, a microarray-based analytical platform that offers rapid, easy-to-use, at-line methods for mRNA characterization in addition to solutions for traditional vaccines.
The VaxArray platform, which has been serving the vaccine industry since 2014, expanded its offerings to include mRNA detection and characterization assays. One of the key innovations is the 5′CapQ assay, which measures the total amount of intact mRNA in a sample by capturing the 5′ cap and labeling the 3′ polyA tail. This assay provides a single measurement of intact mRNA, offering both relative and absolute quantification options.
Aldevron provided the samples used in this assay, which resulted in clean, fast and quantitative results. Working together, InDevR made a significant advancement in mRNA analytics. GEN Magazine featured the whitepaper that outlined the results.